Blood Disorders Overtake Cancer On EMA’s PRIME Scheme
uniQure has become the third company to get accepted on the European Medicines Agency’s PRIME (priority medicines) scheme for a gene therapy for hemophilia, making hematology-hemostaseology the most common therapeutic areas for products on the scheme.
You may also be interested in...
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
Companies won’t necessarily lose their place on the European Medicines Agency’s priority medicines scheme if a competing product gets to market first. And they shouldn’t be put off by the fact that competing products are already on the scheme.
UniQure’s gene therapy, AMT-060, has been accepted into the European Medicines Agency’s priority medicines scheme, PRIME, a move likely to intensify the race to market of a small group of gene therapies for hemophilia B, all currently in Phase I/II studies.